Novo Nordisk Stock Drops Further on Bank of America Downgrade

Novo Nordisk (NVO) shares extended their sharp decline, falling 6% Wednesday following Tuesday's 22% drop, after the company significantly lowered its 2025 sales growth outlook to 8%-14% from 13%-21% and announced a new CEO. This downward revision prompted Bank of America to downgrade the stock to "neutral" and reduce its price target, citing anticipated earnings pressure through 2027. The sustained sell-off underscores significant investor concern regarding the future growth trajectory and profitability of the pharmaceutical giant, with U.S.-listed shares having lost over 40% of their value in 2025.

Analysis

Novo Nordisk (NVO) is experiencing a severe repricing event, evidenced by a two-day stock decline totaling approximately 28%, with a 22% drop on Tuesday followed by a 6% fall on Wednesday. The primary catalyst for this sell-off was the company's significant downward revision of its 2025 sales growth forecast to a range of 8%-14% from a previous 13%-21%, a move that coincided with the announcement of a new CEO, amplifying market uncertainty. The negative momentum was compounded by a Bank of America downgrade from "buy" to "neutral," accompanied by a substantial price target reduction to 375 from 550 Danish kroner. The bank's rationale points to a deteriorating long-term outlook, with reduced earnings forecasts extending through 2027 due to anticipated pressure. This sequence of events has erased over 40% of the stock's value in 2025 and approximately 60% over the past year, indicating a fundamental shift in investor perception regarding the future profitability and growth trajectory of its blockbuster drugs, Ozempic and Wegovy.

Key Decisions for Investors

• Given the magnitude of the guidance cut and the multi-year earnings pressure cited by Bank of America, investors should reassess their long-term growth thesis for Novo Nordisk's weight-loss drug franchise.
• Potential investors should exercise caution before initiating a new position, as the sharp downward momentum and analyst downgrades suggest further price volatility is likely.
• Monitor for strategic communications from the new CEO, as their plans to address the decelerating growth and restore confidence will be critical to establishing a new valuation floor for the stock.
• Traders should be aware that the stock's technical breakdown, which has seen it lose 60% of its value in 12 months, may lead to further downside pressure from forced selling or momentum-based strategies.